Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03166891 | Phase Ib Study of Chiauranib in Patients With Ovarian Cancer | completed | Phase 1 / Phase 2 | 25 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01237067 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | completed | Phase 1 | 77 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01954355 | LDE225 and Paclitaxel in Solid Tumors | completed | Phase 1 | 30 | Swiss Cancer InstituteOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT03411980 | Pharmacokinetics and Safety of Vilaprisan in Renal Impairment | completed | Phase 1 | 26 | BayerINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04157491 | Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer | unknown | Phase 1 / Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00005858 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | completed | Phase 1 | 25 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00478452 | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients(DC-Ova) | completed | Phase 1 | 14 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01445418 | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | completed | Phase 1 | 103 | National Cancer Institute (NCI)NIH | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer(REPROVe) | withdrawn | Phase 1 / Phase 2 | 0 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT00846612 | Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer | completed | Phase 1 | 15 | NYU Langone HealthOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02849340 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02849353 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | terminated | Phase 1 | 20 | Almac DiscoveryINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01375699 | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | completed | Phase 1 | 26 | Virginia Commonwealth UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02045368 | Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | completed | Phase 1 | 92 | IGF Oncology, LLCINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02520115 | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | completed | Phase 1 | 50 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT02179970 | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers(CAM-PLEX) | completed | Phase 1 | 26 | CCTU- Cancer ThemeOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04029909 | A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | unknown | Phase 1 | 12 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00079430 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 113 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02530047 | Mesenchymal Stem Cells (MSC) for Ovarian Cancer | completed | Phase 1 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01281514 | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | completed | Phase 1 | 21 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT02889848 | Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) | completed | Phase 1 | 15 | Advance Biofactures CorporationINDUSTRY | 1 | Jul 10, 2019 | clinicaltrials |
| NCT03239223 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 16 | Antiva BiosciencesINDUSTRY | 2 | Jul 10, 2019 | clinicaltrials |
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | completed | Phase 1 / Phase 2 | 9 | AdaptimmuneINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)(AL3818) | terminated | Phase 1 / Phase 2 | 12 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | completed | Phase 1 / Phase 2 | 14 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT00357448 | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | completed | Phase 1 | 11 | University of WashingtonOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT00862355 | Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer | completed | Phase 1 | 24 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 98 | Verastem, Inc.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01230996 | Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer(DEPICT) | completed | Phase 1 / Phase 2 | 22 | Barts & The London NHS TrustOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03916679 | MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 22, 2020source: clinicaltrials